Navigation Links
ExonHit Therapeutics: Allergan and ExonHit's First Collaboration Compound to Begin Human Clinical Trials
Date:8/27/2007

ates of ExonHit Therapeutics which may be contained herein are for illustrative purposes only and are based on management's current views and assumptions. Such projections, forecast and estimates involve known and unknown risks and uncertainties, as described at Section 4.2 "Facteurs de risque" (Risk Factors) of the Document de Base available on ExonHit Therapeutics' website (http://www.exonhit.com), that may cause actual results, performance or events to differ materially from those anticipated in the summary information.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

Contacts

ExonHit Therapeutics

Bruno Tocque, C.E.O.

Tel: +33-1-58-05-47-00

Philippe Rousseau, C.F.O.

philippe.rousseau@exonhit.com


'/>"/>
SOURCE ExonHit Therapeutics SA
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. Midwest life science stocks sizzle in a tepid first quarter
3. Morgridge Institute for Research seeks first CEO
4. Sonic Foundry reports first cash-positive quarter
5. Angel investors commit $12.7B in first half of `06
6. Aurora team implants Wisconsins first total artificial heart
7. First half of 2006 roundup: Big Pharma trumps biotech
8. GE announces first installation of Discovery VCT
9. GE Healthcare enjoys robust growth in first quarter
10. Madison asks for wireless bids; airport, downtown would be first
11. Tech Digest: Inacom, PKWare at Infosecurity, Firstlogic, Teklynx
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Newly discovered mechanism allows cells to change state 2More than fish bait: Worms unlock secrets to new epilepsy treatments 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 3ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 4PDL BioPharma to Present at Oppenheimer 26amp 3B Co 20th Annual Healthcare Conference on November 4 2009 14619 1Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 1Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 2Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 3Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 4Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 5Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 6Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 7Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 8Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 1Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 2Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 3Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 4Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 5Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 6Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 7Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 8Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 9Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 10Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 11Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 12Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 13Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 14Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 15Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 16Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 17Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 18Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 19Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 20Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 21Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 22